Welcome to our dedicated page for Neurogene news (Ticker: NGNE), a resource for investors and traders seeking the latest updates and insights on Neurogene stock.
Neurogene Inc. (Nasdaq: NGNE) generates news primarily around its gene therapy programs for rare neurological diseases, with a central focus on NGN-401 for Rett syndrome. As a clinical-stage company, Neurogene regularly issues updates on clinical trial progress, interim data, regulatory interactions and corporate developments.
Recent press releases highlight multiple milestones for NGN-401, including dosing of participants in the Embolden registrational trial, initiation of numerous U.S. clinical trial sites, and positive interim data from the Phase 1/2 trial in pediatric and adolescent/adult cohorts. These updates describe multidomain, durable functional gains and developmental milestone acquisition in females with Rett syndrome, along with safety observations at the 1E15 vg dose.
Visitors to this NGNE news page can review announcements on trial design for Embolden, preclinical data comparing intracerebroventricular and intrathecal lumbar delivery, and regulatory designations from the FDA, EMA and UK MHRA. Neurogene also reports on participation in healthcare and genetic medicines conferences, where management presents company overviews and clinical data, as well as on financial results and cash runway disclosures through quarterly earnings releases.
Additional news items cover corporate matters such as inducement grants under Nasdaq Listing Rule 5635(c)(4) and updates furnished via Form 8-K. For investors and followers of Rett syndrome research, the NGNE news stream provides a consolidated view of Neurogene’s clinical progress, regulatory status and operational execution around NGN-401 and its broader gene therapy platform over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.